Sofosbuvir Compulsory License Nears In Chile
Executive Summary
Generic competition is nearing for hepatitis C medicines formulated with Gilead’s sofosbuvir in Chile, following moves by the health ministry to allow compulsory licensing.
You may also be interested in...
Use Of Compulsory Licensing ‘More Frequent Than Commonly Assumed’
A report in the WHO Bulletin says that the use of the TRIPS flexibilities has been much greater than is commonly assumed, dispelling the belief that such use has been sporadic and limited.
Chilean Lawmakers Back Sofosbuvir Compulsory Licensing
Chile’s lower house of congress has backed a resolution calling for the government to set the scene for the compulsory licensing of hepatitis C drugs.
Astellas and Gilead In Spotlight As Compulsory Licensing Pressure Mounts In Chile
Pressure is mounting in Chile for the government to pursue compulsory licensing. Gilead’s Sovadi (sofosbuvir) and Astellas’s prostate cancer drug Xtandi (enzalutamide) could be among the drugs eventually opened up to generic competition.